Databases containing raw analytical data obtained in the SEROCOV-1 and SEROCOVAC studies and personal covariates used in the publication Moncunill G, Aguilar R, et al EBioMedicine. 2022 Jan 11;75:103805. doi: 10.1016/j.ebiom.2021.103805. Data correspond to antibody levels to SARS-CoV-2 and four seasonal coronaviruses, and the neutralization capacity of samples from 578 participants recruited from 28 March- 9 April 2020, and the follow-up visits after one, three, six, nine and twelve months. In months 9 and 12, data on vaccination status was collected and some participants had already received the 1st (N=64) or the 2nd doses (N=4). Month 12 follow-up mostly included participants who had a blood sample taken two weeks post 2nd dose. The analytical data is completed with participants' information on occupation, comorbidities, previous COVID19 diagnoses and other sociodemographic characteristics. The code was developed using R version 4.0.3.

This proposal aims at shedding light on the levels of exposure to SARS-Cov-2 at the Hospital Clínic of Barcelona, one of the reference centers in Spain for the diagnosis and treatment of COVID-19 disease. Data generated will have direct implications in human resources management and planning in the health system, as well as in the understanding of the different microbiological, clinical, immunological and nosocomial determinants of the disease and its transmission.